This information is current as Fibroblasts Does Not Activate Signaling in Human Lung Mediated Responses but − Attenuates IL-13 2 α Endogenously Expressed IL-13 R

[1]  Ruksha Bhadresha.  Dupilumab in persistent asthma with elevated eosinophil levels , 2013, Thorax.

[2]  M. Ultsch,et al.  Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. , 2013, Journal of molecular biology.

[3]  K. Leslie.  Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis. , 2012, Archives of pathology & laboratory medicine.

[4]  S. Mosesova,et al.  Lebrikizumab Treatment Reduces Serum Periostin Levels In Asthma Patients With Elevated Baseline Levels Of Periostin , 2012, ATS 2012.

[5]  D. Sheppard,et al.  Alternaria Induces STAT6-Dependent Acute Airway Eosinophilia and Epithelial FIZZ1 Expression That Promotes Airway Fibrosis and Epithelial Thickness , 2012, The Journal of Immunology.

[6]  Lee， Jk,et al.  Lebrikizumab treatment in adults with asthma. , 2011 .

[7]  T. Wynn,et al.  Accelerated and progressive and lethal liver fibrosis in mice that lack interleukin (IL)-10, IL-12p40, and IL-13Rα2. , 2011, Gastroenterology.

[8]  Nicola A Hanania,et al.  Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.

[9]  Thomas A. Wynn,et al.  Integrating mechanisms of pulmonary fibrosis , 2011, The Journal of experimental medicine.

[10]  K. Marquette,et al.  IL-13 Antibodies Influence IL-13 Clearance in Humans by Modulating Scavenger Activity of IL-13Rα2 , 2011, The Journal of Immunology.

[11]  L. Boulet,et al.  Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. , 2011, American journal of respiratory and critical care medicine.

[12]  M. Kaplan,et al.  Transcriptional regulation by STAT6 , 2011, Immunologic research.

[13]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[14]  Barmak Modrek,et al.  Gene Expression Patterns of Th2 Inflammation and Intercellular Communication in Asthmatic Airways , 2011, The Journal of Immunology.

[15]  S. Kato,et al.  Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias , 2010, European Respiratory Journal.

[16]  K. Garcia,et al.  Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2. , 2010, Structure.

[17]  C. Oh,et al.  Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma , 2010, European Respiratory Review.

[18]  Barmak Modrek,et al.  T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.

[19]  S. Uh,et al.  Interleukin-13 and Its Receptors in Idiopathic Interstitial Pneumonia: Clinical Implications for Lung Function , 2009, Journal of Korean medical science.

[20]  J. Hopkin,et al.  RNA interference of STAT6 rapidly attenuates ongoing interleukin‐13‐mediated events in lung epithelial cells , 2009, Immunology.

[21]  M. Olschewski,et al.  Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.

[22]  E. Geissler,et al.  IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. , 2008, Gastroenterology.

[23]  A. Bree,et al.  Interleukin-13 Neutralization by Two Distinct Receptor Blocking Mechanisms Reduces Immunoglobulin E Responses and Lung Inflammation in Cynomolgus Monkeys , 2008, Journal of Pharmacology and Experimental Therapeutics.

[24]  A. Murphy,et al.  Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor α1 chain , 2008, Nature Immunology.

[25]  R. Homer,et al.  IL-13 Receptor α2 Selectively Inhibits IL-13-Induced Responses in the Murine Lung1 , 2008, The Journal of Immunology.

[26]  Yee Hwa Yang,et al.  Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids , 2007, Proceedings of the National Academy of Sciences.

[27]  G. Oster,et al.  Incidence and prevalence of idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.

[28]  Naftali Kaminski,et al.  Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. , 2006, American journal of respiratory and critical care medicine.

[29]  Biao Hu,et al.  Regulation of Found in Inflammatory Zone 1 Expression in Bleomycin-Induced Lung Fibrosis: Role of IL-4/IL-13 and Mediation via STAT-61 , 2004, The Journal of Immunology.

[30]  T. Moore,et al.  Protection from Fluorescein Isothiocyanate-Induced Fibrosis in IL-13-Deficient, but Not IL-4-Deficient, Mice Results from Impaired Collagen Synthesis by Fibroblasts1 , 2004, The Journal of Immunology.

[31]  T. Wynn,et al.  IL-13 receptor alpha 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Burdick,et al.  Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. , 2002, American journal of respiratory cell and molecular biology.

[33]  R. Homer,et al.  Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor β1 , 2001, The Journal of experimental medicine.

[34]  B. Ma,et al.  Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. , 2000, The Journal of clinical investigation.

[35]  B. Antus,et al.  Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. , 2000, Cellular immunology.

[36]  T. Wynn,et al.  An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. , 1999, The Journal of clinical investigation.

[37]  R. Homer,et al.  Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. , 1999, The Journal of clinical investigation.

[38]  S. Goerdt,et al.  Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. , 1998, Journal of immunology.

[39]  R. de Waal Malefyt,et al.  Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Retraction. Elevated IL-13Ra2 in Intestinal Epithelial Cells From Ulcerative Colitis or Colorectal Cancer Initiates MAPK Pathway. , 2015, Inflammatory bowel diseases.

[41]  S. Rosselot.  Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[42]  A. Prasse,et al.  CCL 18 as an Indicator of Pulmonary Fibrotic Activity in Idiopathic Interstitial Pneumonias and Systemic Sclerosis , 2007 .

[43]  R. Puri,et al.  IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis , 2006, Nature Medicine.

[44]  Terry J. Smith,et al.  Isolation and phenotypic characterization of lung fibroblasts. , 2005, Methods in molecular medicine.

[45]  R. Puri,et al.  Therapeutic targeting of IL-4-and IL-13-responsive cells in pulmonary fibrosis , 2004, Immunologic research.